Coadministration with CYP3A4 substrates, specifically These using a slim therapeutic index, can result in decreased concentrations and loss of efficacy. If unable to avoid coadministration, keep track of CYP3A4 substrate amounts and modify dose as necessary.atazanavir will enhance the amount or influence of triazolam by impacting hepatic/intestinal